<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138890</url>
  </required_header>
  <id_info>
    <org_study_id>BBI.CR.APS1.14</org_study_id>
    <nct_id>NCT02138890</nct_id>
  </id_info>
  <brief_title>APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)</brief_title>
  <acronym>PROGRESS II</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution (APS) in Patients With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, multicenter, randomized, controlled trial (RCT) will evaluate the efficacy
      of a single dose of Autologous Protein Solution (APS) in patients with osteoarthritis (OA) of
      the knee who have failed at least 1 conservative osteoarthritis (OA) therapy (e.g.
      physiotherapy, simple analgesics, intra-articular injection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the
      efficacy of a single dose of Autologous Protein Solution (APS) in patients with
      Osteoarthritis (OA) of the knee who have failed at least 1 conservative OA therapy (e.g.
      physiotherapy, simple analgesics, intra-articular injection).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale - Pain</measure>
    <time_frame>60 Month</time_frame>
    <description>Pain will be measured utilizing patient surveys</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score - Function</measure>
    <time_frame>60 months</time_frame>
    <description>Knee function will be measured utilizing patient surveys and knee examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score - Stiffness</measure>
    <time_frame>60 months</time_frame>
    <description>Knee stiffness will be measured utilizing patient surveys and knee examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Imaging - Joint Structure</measure>
    <time_frame>24 months</time_frame>
    <description>Joint structure will be examined radiographically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires (QoL)</measure>
    <time_frame>60 months</time_frame>
    <description>QoL will be assessed utilizing Quality of Life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (Safety)</measure>
    <time_frame>60 months</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>APS injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Protein Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>APS</intervention_name>
    <description>Intra-articular Injection</description>
    <arm_group_label>APS injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intra-articular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥40 years and ≤75 years.

          -  Willingness and ability to comply with the study procedures and visit schedules and
             ability to follow verbal and written instructions.

          -  Diagnosis of knee osteoarthritis (OA) Grade 2 or 3 according to the Kellgren-Lawrence
             scale

          -  Body mass index (BMI) ≤ 40.

          -  Failed at least 1 conservative OA therapy

          -  Signed an independent ethics committee (IEC) approved informed consent form (ICF).

        Exclusion Criteria:

        - Intra-articular Hyaluronic (HA) injection within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Kon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bologna (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krems Hospital</name>
      <address>
        <city>Krems</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monica Hospitals</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <disposition_first_submitted>August 22, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 22, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 23, 2016</disposition_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous Protein Solution</keyword>
  <keyword>APS</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Intra Articular Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 27, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

